The final segment of this roundtable series addresses the future of immunotherapy combinations. The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer. In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed. The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments. In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed. The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial